A. V. van Schoonhoven

Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment

K. Khunti, M. Postma, P. Patel, 2018, Hypertension.

Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands

M. Postma, B. van Hoek, L. D. de Jong, 2021, Journal of medical economics.

The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands

Marten Postma, E. Serné, C. Boersma, 2023, Journal of medical economics.

Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review

M. Postma, J. V. van Boven, A. V. van Asselt, 2019, PloS one.

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands

A. V. van Schoonhoven, Sara W. Quist, Stephan J. L. Bakker, 2023, Cardiovascular Diabetology.